Tourmaline Bio, Inc. Common Stock
Symbol: TRML (NASDAQ)
47.60
▼ (-0.09%) -0.045
Company Description:
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Key Stats
- Today's Open: $47.62
- Today's High: $47.71
- Today's Low: $47.575
- Today's Volume: 2.21M
- Yesterday Close: $47.64
- Yesterday High: $47.69
- Yesterday Low: $47.57
- Yesterday Volume: 22.67M
- Last Min Volume: 956
- Last Min High: $47.595
- Last Min Low: $47.595
- Last Min VWAP: $47.595
Company Profile
- Name: Tourmaline Bio, Inc. Common Stock
- Website: https://www.tourmalinebio.com
- Listed Date: 2023-10-19
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001827506
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $775.39M
- Round Lot: 100
- Outstanding Shares: 25.69M
- Asset Type: CS
RECENT FILINGS FOR TRML
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-09 | 4 | View |
| 2025-09-09 | SC14D9C | View |
| 2025-09-09 | SC TO-C | View |
| 2025-09-09 | SC14D9C | View |
| 2025-09-09 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-06-09 | 8-K | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 8-K | View |
| 2025-05-20 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-02 | 10-Q | View |
Latest News on TRML